

House _____ Amendment NO. _____

Offered By _____

1 AMEND House Committee Substitute for Senate Bill No. 204, Page 49, Section 338.010, Line 103,
2 by inserting after all of said section and line the following:

3
4 "338.095. 1. The terms "prescription" and "prescription drug order" are hereby defined as a
5 lawful order for medications or devices issued and signed by an authorized prescriber within the
6 scope of his professional practice which is to be dispensed or administered by a pharmacist or
7 dispensed or administered pursuant to section 334.104 to and for the ultimate user. The terms
8 "prescription" and "drug order" do not include an order for medication requiring a prescription to be
9 dispensed, which is provided for the immediate administration to the ultimate user or recipient.

10 2. The term "telephone prescription" is defined as an order for medications or devices
11 transmitted to a pharmacist by telephone or similar electronic medium by an authorized prescriber
12 or his authorized agent acting in the course of his professional practice which is to be dispensed or
13 administered by a pharmacist or dispensed or administered pursuant to section 334.104 to and for
14 the ultimate user. A telephone prescription shall be promptly reduced to written or electronic
15 medium by the pharmacist and shall comply with all laws governing prescriptions and record
16 keeping.

17 3. A licensed pharmacist may lawfully provide prescription or medical information to a
18 licensed health care provider or his agent who is legally qualified to administer medications and
19 treatments and who is involved in the treatment of the patient. The information may be derived by
20 direct contact with the prescriber or through a written protocol approved by the prescriber. Such
21 information shall authorize the provider to administer appropriate medications and treatments.

22 4. Nothing in this section shall be construed to limit the authority of other licensed health
23 care providers to prescribe, administer, or dispense medications and treatments within the scope of
24 their professional practice.

25 5. It shall be an unauthorized practice of pharmacy and hence unlawful for any person other
26 than a board licensee or registrant, the patient, or the patient's authorized representative to accept a
27 prescription presented to be dispensed unless that person is located on a premises licensed by the
28 board as a pharmacy.

29 338.140. 1. The board of pharmacy shall have a common seal, and shall have power to
30 adopt such rules and bylaws not inconsistent with law as may be necessary for the regulation of its
31 proceedings and for the discharge of the duties imposed pursuant to sections 338.010 to 338.198,
32 and shall have power to employ an attorney to conduct prosecutions or to assist in the conduct of
33 prosecutions pursuant to sections 338.010 to 338.198.

34 2. The board shall keep a record of its proceedings.

35 3. The board of pharmacy shall make annually to the governor and, upon written request, to
36 persons licensed pursuant to the provisions of this chapter a written report of its proceedings.

Action Taken _____ Date _____

4. The board of pharmacy shall appoint an advisory committee composed of six members, one of whom shall be a representative of pharmacy but who shall not be a member of the pharmacy board, three of whom shall be representatives of wholesale drug distributors as defined in section 338.330, one of whom shall be a representative of drug manufacturers, and one of whom shall be a licensed veterinarian recommended to the board of pharmacy by the board of veterinary medicine. The committee shall review and make recommendations to the board on the merit of all rules and regulations dealing with pharmacy distributors, wholesale drug distributors, drug manufacturers, and veterinary legend drugs which are proposed by the board.

5. A majority of the board shall constitute a quorum for the transaction of business.

6. Notwithstanding any other provisions of law to the contrary, the board may issue letters of reprimand, censure or warning to any holder of a license or registration required pursuant to this chapter for any violations that could result in disciplinary action as defined in section 338.055. Alternatively, at the discretion of the board, the board may enter into a voluntary compliance agreement with a licensee, permit holder, or registrant to ensure or promote compliance with chapter 338 and the rules of the board, in lieu of board discipline. The agreement shall be a public record. The time limitation identified in section 324.043 for commencing a disciplinary proceeding shall be tolled while an agreement authorized by this section is in effect.

338.143. 1. For purposes of this section, the following terms shall mean:

(1) "Remote medication dispensing", dispensing or assisting in the dispensing of medication outside of a licensed pharmacy;

(2) "Technology-assisted verification", the verification of medication or prescription information using a combination of scanning technology and visual confirmation by a pharmacist.

2. The board of pharmacy may approve, modify, and establish requirements for pharmacy pilot or demonstration research projects related to technology-assisted verification or remote medication dispensing that are designed to enhance patient care or safety, improve patient outcomes, or expand access to pharmacy services.

3. To be approved, pilot or research projects shall be within the scope of the practice of pharmacy as defined in chapter 338, be under the supervision of a Missouri-licensed pharmacist, and comply with applicable compliance and reporting requirements established by the board by rule, including any staff training or education requirements. Board approval shall be limited to a period of up to eighteen months, provided that the board may grant an additional six-month extension if deemed necessary or appropriate to gather or complete research data or if deemed in the best interests of the patient. The board may rescind approval of a pilot project at any time if deemed necessary or appropriate in the interest of patient safety.

4. The provisions of this section shall expire on August 28, 2023. The board shall provide a final report on approved projects and related data or findings to the general assembly on or before December 31, 2022. The name, location, approval dates, supervising pharmacist, and a general description of an approved pilot or research project shall be deemed an open record."; and

Further amend said bill by amending the title, enacting clause, and intersectional references accordingly.